2) @IgAN_JBarratt attended #KidneyWk 2023 and collected the best #IgAN highlights to share with our followers and learners here on @ckd_ce, your ONLY home for π#renal CE/#CME delivered wholly on X!
— @CKD_ce (@ckd_ce) December 5, 2023
4a) @IgAN_JBarratt reports that #ASN2023 was certainly a highlight for those of us interested in #IgAN. For the first time the exhibition hall was full of companies developing new drugs for IgAN . . .
— @CKD_ce (@ckd_ce) December 5, 2023
5a) The complete data for the #PROTECT trial
— @CKD_ce (@ckd_ce) December 5, 2023
π https://t.co/ea8On2aa6W
of the dual endothelin angiotensin receptor antagonist #DEARA #Sparsentan was presented by @BradRovin to a packed auditorium with a simultaneous publication in @TheLancet:https://t.co/IRF9NniTNY pic.twitter.com/MwvVdtsdXp
6a) Another trial with data likely to impact on #IgAN management in the future is the Ph 2b #ZENITH-CKD study
— @CKD_ce (@ckd_ce) December 5, 2023
π https://t.co/IzSutkHAYw
by @HeerspinkHiddo, again with simul-pub in @TheLancet:https://t.co/fJnD1JTiZb. pic.twitter.com/MyXXK1MTrR
7) Keeping the #ERA theme going πhttps://t.co/vaq3CTlSR2, we also saw the study design for the #ASSISTtrial looking at combination treatment with #Atrasentan and #SGLT2i in #IgAN:
— @CKD_ce (@ckd_ce) December 5, 2023
π https://t.co/yxwE0wtJNB
9a) Full data presented on Ph2 #ENVISION trial:
— @CKD_ce (@ckd_ce) December 5, 2023
π https://t.co/z7eoWEmCu0 by yours truly @IgAN_JBarratt on the #APRIL inhibitor #Sibeprenlimab. APRIL = A Proliferation-Inducing Ligand. Learn more πhttps://t.co/GfSgdh9R59.
ENVISION simul-pub in @NEJM:https://t.co/XAoPkmncrR pic.twitter.com/yiutc3IzG2
10) The Ph3 trial of #Sibeprenlimab, #VISIONARYhttps://t.co/NvlQdap1Vi is recruiting; data should be available in 2024-25. A trial in progress poster was also presented for the Ph 3 BEYOND Study of #Zigakibart, another #APRIL inhibitor, in #IgAN π https://t.co/IsJueiy8y7
— @CKD_ce (@ckd_ce) December 5, 2023
11b) #Atacicept, in the now completed & soon to be published Ph2b #ORIGIN trial (learn more from me at πhttps://t.co/wNYCQk24gR), significantly β¬οΈ#Gd_IgA1 β‘οΈboth β¬οΈproteinuria & β¬οΈ#haematuria
— @CKD_ce (@ckd_ce) December 5, 2023
See π https://t.co/GEuxd0ZKrg, while also . . . pic.twitter.com/wS66zHQLCl
11d) We also saw data for #Povetacicept in #IgAN for the 1st timehttps://t.co/aGiZDDv6ib
— @CKD_ce (@ckd_ce) December 5, 2023
from the #RUBY_3 study
π https://t.co/VxOxycr0pw pic.twitter.com/F94W8wr7lu
12a) Moving on now to #Nefecon, the first @US_FDA approved treatment for #IgAN, having presented the complete study data earlier in the year at #ERA2023 and published in @TheLancet https://t.co/gBRx1fNGAn pic.twitter.com/3ksti45EdG
— @CKD_ce (@ckd_ce) December 5, 2023
12c) Expect a paper in @Kidney_Int before the end of the year describing the #biomarker analyses from the Ph2 #NefIgAN study. Primary analysis already published at https://t.co/JiovVNUhov
— @CKD_ce (@ckd_ce) December 5, 2023
12e) Perhaps most interesting was the analysis looking at the response in Chinese patients β‘οΈ #Nefecon works as effectively in Chinese patients as in white patients.
— @CKD_ce (@ckd_ce) December 5, 2023
π https://t.co/2UfrcqktrN pic.twitter.com/QVUFnBoLV7
13b) #Ravulizumab treatment effectively reduced C5 levels and complement activation in #IgAN and led to a rapid reduction in proteinuria consistent with inhibition of complement-mediated glomerular inflammation. Expect a Ph3 study soon!
— @CKD_ce (@ckd_ce) December 5, 2023
π https://t.co/qYb56IV3PQ pic.twitter.com/uFHkva1fxP
14b) This novel #RNA interference therapeutic (learn more at https://t.co/3TIQfWQ3XF) appears to reduce Complement Factor B synthesis in the liver & reduce alternative pathway activation. pic.twitter.com/W5SU33wxlP
— @CKD_ce (@ckd_ce) December 5, 2023
15a) To finish we had new data presented from the UK #RaDaR #IgAN cohort. (See π https://t.co/BRyBSALkZZ)
— @CKD_ce (@ckd_ce) December 5, 2023
Consistent with prior data from https://t.co/b5ypEkGAew) we saw at #KidneyWk data from #CureGN (https://t.co/9x5aTEPZPI):https://t.co/ky6FkrumEh pic.twitter.com/q2VOzso37Z
16) Confirming poor outcomes in patients with #IgAN we saw data for the first time from a large πΊπΈ cohort
— @CKD_ce (@ckd_ce) December 5, 2023
π https://t.co/1b00TqzzDE.
I look forward to seeing the full publication! pic.twitter.com/HBtxFKy8jD
17b) . . . and a study from #Manitoba π¨π¦ confirming outcomes with current treatment approaches are poor for young people with #IgAN:
— @CKD_ce (@ckd_ce) December 5, 2023
π https://t.co/Uk414K5tHL pic.twitter.com/jVg0SHTcOQ
18b) It's 3, #sparsentan. Learn more about this (and get more πCE/#CME) at https://t.co/yoOZZu9EEM from @didemturgut_ and https://t.co/2QuD4w9mii from @HecmagsMD.
— @CKD_ce (@ckd_ce) December 5, 2023
Now, which of the following drugs has been shown to inhibit #APRIL-driven #Gd_IgA1 production in #IgAN?
20) .@ckd_ce π @IgAN_JBarratt for this #IgAN tour of #KidneyWk 2023, and we all thank YOU for joining & learning! You can now claim your 0.75hr π CE/#CME at https://t.co/qyipnlokeJ . . . and then FOLLOW US for the only #tweetorial-delivered #MedEd in the π« space! pic.twitter.com/bo8FyW5kbl
— @CKD_ce (@ckd_ce) December 5, 2023